Nanomedicine and Gut-Brain Axis

Ibrahim's research focuses on the pharmacological and pharmaceutical interventions along Gut-Brain axis. He is exploring the biochemical involvement of infectious gut-microbes in protein-aggregation and neurodegeneration diseases and using this knowledge to drive rationale synthesis of nano-pharmaceuticals, specifically for the synthesis of pharmaceutically functional nano-materials, drug delivery carriers and their interfacial interactions with amyloid proteins like human Islet Amyloid Polypeptide, Amyloid-beta and alpha-Synuclein that are involved in the pathogenesis of type-2-diabetes, Alzheimer's and Parkinson's diseases.

​r. Ibrahim Javed is Postdoctoral Research Fellow at ARC Centre of Excellence in Convergent Nano-Bio Science and Technology and Australian Institute for Bioengineering and Nanotechnology at The University of Queensland. He earned his PhD degree from Monash Institute of Pharmaceutical Sciences at Monash University in 2019. Prior to PhD, Dr. Javed had graduated with Doctor of Pharmacy degree in 2011 from University of Sargodha and Master of Philosophy in Pharmaceutical Chemistry in 2014 from Bahauddin Zakariya University, Pakistan. With extensive research experience in the synthesis of pharmaceutical nanomaterials, in vivo modelling, pharmacokinetics and protein misfolding and aggregation, his research has been published in prestigious journals like Nature Communications, Nano Letter, Small,  ACS Applied Materials & Interfaces, Nanoscale, Biomacromolecules and Journal of Materials Chemistry B.


​Ibrahim is working with a number of national and international collaborations including Prof. Clare Parish at The Florey Institute, Prof. Sijie Lin at Tongji University, A/Prof. Feng Ding from Clemson University, Prof. Raffaele Mezzenga at ETH and Prof. Daniel Otzen from Aarhus University. 

Key Publications

​Javed, I., Peng, G., Xing, Y., Yu, T., Zhao, M., Kakinen, A., Faridi, A., Parish, C.L., Ding, F., Davis, T.P., Ke, P.C. and Lin, S., 2019. Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy. Nature communications, 10(1), pp.1-14.

Javed, I., Yu, T., Peng, G., Sánchez-Ferrer, A., Faridi, A., Kakinen, A., Zhao, M., Mezzenga, R., Davis, T.P., Lin, S. and Ke, P.C., 2018. In vivo mitigation of amyloidogenesis through functional–pathogenic double-protein coronae. Nano letters, 18(9), pp.5797-5804.

Kakinen, A., Xing, Y., Hegoda Arachchi, N., Javed, I., Feng, L., Faridi, A., Douek, A.M., Sun, Y., Kaslin, J., Davis, T.P., Higgins, M.J., Ding, F. and Ke, P.C., 2019. Single-Molecular Heteroamyloidosis of Human Islet Amyloid Polypeptide. Nano letters, 19(9), pp.6535-6546.

Ke, P.C., Pilkington, E.H., Sun, Y., Javed, I., Kakinen, A., Peng, G., Ding, F. and Davis, T.P., 2019. Mitigation of amyloidosis with nanomaterials. Advanced Materials, p.1901690.

Ke, P.C., Sani, M.A., Ding, F., Kakinen, A., Javed, I., Separovic, F., Davis, T.P. and Mezzenga, R., 2017. Implications of peptide assemblies in amyloid diseases. Chemical Society Reviews, 46(21), pp.6492-6531.


​NHMRC Emerging Leadership Investigator Grant